Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Michael

Showing results (1221-1230 of 1,306) with videos related to

Pageof 131
Sort By:
European Journal of Heart Failure|May 16, 2018
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetesAbhinav Sharma, Sana M Al-Khatib, Justin A Ezekowitz, et al.
Medrxiv : the Preprint Server for Health Sciences|October 27, 2022
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical TrialMatthew W McCarthy, Susanna Naggie, David R Boulware, et al.
Journal of Cardiac Failure|September 8, 2023
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFKieran F Docherty, John J V McMurray, Rafael Diaz, et al.
JAMA|January 12, 2023
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical TrialMatthew W McCarthy, Susanna Naggie, David R Boulware, et al.
European Journal of Heart Failure|January 4, 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trialKieran F Docherty, John J V McMurray, Brian L Claggett, et al.
Circulation|May 20, 2015
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) StudyMichael M Givertz, Kevin J Anstrom, Margaret M Redfield, et al.
PLOS Global Public Health|July 16, 2024
Effectiveness of community-based interventions for prevention and control of hypertension in sub-Saharan Africa: A systematic reviewEndalkachew Worku Mengesha, Tadesse Dagget Tesfaye, Minyahil Tadesse Boltena, et al.
JAMA Network Open|December 3, 2025
Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical TrialCongying Xia, Amanda M Smith, Bénédicte Lefebvre, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 26, 2014
Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgeryMichael J Reardon, David H Adams, Joseph S Coselli, et al.
Journal of the American College of Cardiology|June 11, 2016
Aortic Dissection in Patients With Genetically Mediated Aneurysms: Incidence and Predictors in the GenTAC RegistryJonathan W Weinsaft, Richard B Devereux, Liliana R Preiss, et al.
Pageof 131

Showing results (1221-1230 of 1,306) with videos related to

Sort By:
Pageof 131
European Journal of Heart Failure|May 16, 2018
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetesAbhinav Sharma, Sana M Al-Khatib, Justin A Ezekowitz, et al.
Medrxiv : the Preprint Server for Health Sciences|October 27, 2022
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical TrialMatthew W McCarthy, Susanna Naggie, David R Boulware, et al.
Journal of Cardiac Failure|September 8, 2023
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFKieran F Docherty, John J V McMurray, Rafael Diaz, et al.
JAMA|January 12, 2023
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical TrialMatthew W McCarthy, Susanna Naggie, David R Boulware, et al.
European Journal of Heart Failure|January 4, 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trialKieran F Docherty, John J V McMurray, Brian L Claggett, et al.
Circulation|May 20, 2015
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) StudyMichael M Givertz, Kevin J Anstrom, Margaret M Redfield, et al.
PLOS Global Public Health|July 16, 2024
Effectiveness of community-based interventions for prevention and control of hypertension in sub-Saharan Africa: A systematic reviewEndalkachew Worku Mengesha, Tadesse Dagget Tesfaye, Minyahil Tadesse Boltena, et al.
JAMA Network Open|December 3, 2025
Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical TrialCongying Xia, Amanda M Smith, Bénédicte Lefebvre, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 26, 2014
Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgeryMichael J Reardon, David H Adams, Joseph S Coselli, et al.
Journal of the American College of Cardiology|June 11, 2016
Aortic Dissection in Patients With Genetically Mediated Aneurysms: Incidence and Predictors in the GenTAC RegistryJonathan W Weinsaft, Richard B Devereux, Liliana R Preiss, et al.
Pageof 131